Fate Therapeutics Inc (NASDAQ:FATE) has a beta value of 2.25 and has seen 2.13 million shares traded in the recent trading session. The company, currently valued at $193.05M, closed the recent trade at $1.70 per share which meant it gained $0.28 on the day or 19.37% during that session. The FATE stock price is -419.41% off its 52-week high price of $8.83 and 38.82% above the 52-week low of $1.04. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.45 million shares traded. The 3-month trading volume is 3.20 million shares.
The consensus among analysts is that Fate Therapeutics Inc (FATE) is Buy stock at the moment, with a recommendation rating of 2.44. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.43.
Fate Therapeutics Inc (NASDAQ:FATE) trade information
Sporting 19.37% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the FATE stock price touched $1.70 or saw a fall of -2.08%. Year-to-date, Fate Therapeutics Inc shares have moved 2.73%, while the 5-day performance has seen it change 35.60%. Over the past 30 days, the shares of Fate Therapeutics Inc (NASDAQ:FATE) have changed 35.60%. Short interest in the company has seen 12.87 million shares shorted with days to cover at 5.71.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 66.0% from the levels at last check today. The projected low price target is $5.0 while the price target rests at a high of $5.0. In that case, then, we find that the latest price level in today’s session is -194.12% off the targeted high while a plunge would see the stock gain -194.12% from the levels at last check today.
Fate Therapeutics Inc (FATE) estimates and forecasts
The company’s shares have lost -50.00% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -78.70%.
13 analysts offering their estimates for the company have set an average revenue estimate of 1.51M for the current quarter. 9 have an estimated revenue figure of 1.24M for the next ending quarter. Year-ago sales stood 1.68M and 1.93M respectively for this quarter and the next, and analysts expect sales will shrink by -9.93% for the current quarter and -78.70% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -6.65% over the past 5 years. Earnings growth for 2025 is a modest 0.43% while over the next 5 years, the company’s earnings are expected to increase by 1.90%.
FATE Dividends
Fate Therapeutics Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Fate Therapeutics Inc (NASDAQ:FATE)’s Major holders
Insiders own 2.28% of the company shares, while shares held by institutions stand at 90.41% with a share float percentage of 92.52%. Investors are also buoyed by the number of investors in a company, with Fate Therapeutics Inc having a total of 212.0 institutions that hold shares in the company. The top two institutional holders are REDMILE GROUP, LLC with over 13.17 million shares worth more than $43.19 million. As of 2024-06-30, REDMILE GROUP, LLC held 11.2107% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 10.57 million shares as of 2024-06-30. The firm’s total holdings are worth over $34.67 million and represent 10.4544% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Sep 30, 2024, the former fund manager holds about 2.68% shares in the company for having 3.05 shares of worth $5.06 million while later fund manager owns 2.8 shares of worth $4.65 million as of Nov 30, 2024, which makes it owner of about 2.46% of company’s outstanding stock.
